Clinical Trial Detail

NCT ID NCT01732913
Title Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications

chronic lymphocytic leukemia

follicular lymphoma

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

non-Hodgkin lymphoma

Therapies

Idelalisib

Rituximab

Age Groups: adult

No variant requirements are available.